Document is current
Any future updates will be listed below
-
Authors
Chambers, Andrew G.
Chain, David C.
Sweet, Steve M.
Song, Zifeng
Martin, Philip L.
Ellis, Matthew J.
Rooney, Claire
Kim, Yeoun Jin
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 1 September 2023
Accepted: 4 October 2023
First Online: 25 October 2023
Declarations
:
: The use of animal models was approved by an internal Ethical Review Process (ERP) for the development of AZD4625 as previously described and complies with the company’s Global Bioethics Policy. The clinical FFPE tumor tissues from NSCLC patients were obtained following guidance for informed consent determined by separate Institutional Review Boards.
: Not applicable.
: All authors are employees of AstraZeneca and have stock ownership and/or stock options or interests in the company.
